Кристи Фанк - Грудь. Руководство пользователя [litres]

K. Jonsson et al., “Tissue Oxygen Measurements in Delayed Skin Flaps: A Reconsideration of the Mechanisms of the Delay Phenomena,” Plastic and Reconstructive Surgery 82 (1988): 328–335.

B. Palmieri et al., “Delayed Nipple‐Sparing Modified Subcutaneous Mastectomy: Rationale and Technique,” The Breast Journal 11, no. 3 (2005): 173–178.

S. Ghali et al., “Vascular Delay Revisited,” Plastic and Reconstructive Surgery 119 (2007): 1735–1744.

J. A. Jensen et al., “Surgical Delay of the Nipple – Areolar Complex: A Powerful Technique to Maximize Nipple Viability Following Nipple-Sparing Mastectomy,” Annals of Surgical Oncology 19, no. 10 (2012): 3171–3176.

S. L. Spear et al., “Breast Reconstruction Using a Staged Nipple-Sparing Mastectomy Following Mastopexy or Reduction,” Plastic and Reconstructive Surgery 129, no. 3 (2012): 572–581.

R. M. Leach, P. J. Rees, and P. Wilmshurst, “ABC of Oxygen: Hyperbaric Oxygen Therapy,” British Medical Journal 317, no. 7166 (1998): 1140.

C. R. Albornoz et al., “A Paradigm Shift in U. S. Breast Reconstruction: Increasing Implant Rates,” Plastic and Reconstructive Surgery 131, no. 1 (2013): 15–23.

A. K. Alderman et al., “Racial and Ethnic Disparities in the Use of Postmastectomy Breast Reconstruction: Results from a Population-Based Study,” Journal of Clinical Oncology 27, no. 32 (2009): 5325–5330; L. Kruper et al., “Disparities in Reconstruction Rates after Mastectomy: Patterns of Care and Factors Associated with the Use of Breast Reconstruction in Southern California,” Annals of Surgical Oncology 18, no. 8 (2011): 2158–2165.

M. Morrow et al., “Access to Breast Reconstruction after Mastectomy and Patient Perspectives on Reconstruction Decision Making,” JAMA Surgery 149, no. 10 (2014): 1015–1021.

R. J. Bleicher et al., “Time to Surgery and Breast Cancer Survival in the United States,” JAMA Oncology 2, no. 3 (2016): 330–339.

D. J. MacKay and A. L. Miller, “Nutritional Support for Wound Healing,” Alternative Medicine Review 8, no. 4 (2003): 359–378.

P. H. Huang et al., “Emodin and Aloe-emodin Suppress Breast Cancer Cell Proliferation through ERκInhibition,” Evidence-Based Complementary and Alternative Medicine (2013); L. Zhang and I. R. Tizard, “Activation of a Mouse Macrophage Cell Line by Acemannan: The Major Carbohydrate Fraction from Aloe Vera Gel,” Immunopharmacology 35, no. 2 (1996): 119–128.

B. Sweeney et al., “Evidence-Based Systematic Review of Dandelion (Taraxacum Officinale) by Natural Standard Research Collaboration,” Journal of Herbal Pharmacotherapy 5, no. 1 (2005): 79–93.

P. M. Kidd, “Phosphatidyl Choline as an Aid to Liver Function,” Nutrition Science News 1 (1996): 54.

H. Greenlee et al., “Clinical Applications of Silybum Marianum in Oncology,” Integrative Cancer Therapies 6, no. 2 (2007): 158–165.

D. J. MacKay and A. L. Miller, “Nutritional Support for Wound Healing,” Alternative Medicine Review 8, no. 4 (2003): 359–378.

N. Chaiyakunapruk et al., “The Efficacy of Ginger for the Prevention of Postoperative Nausea and Vomiting: A Meta-analysis,” American Journal of Obstetrics and Gynecology 194 (2006): 95–99.

S. Prapaitrakool, A. Itharat, and L. Morinda, “Citrifolia for Prevention of Postoperative Nausea and Vomiting,” Journal of the Medical Association of Thailand 93, no. 7 (2010): S204–209.

J. Webster and S. Osborne, “Preoperative Bathing or Showering with Skin Antiseptics to Prevent Surgical Site Infection,” Cochrane Database of Systematic Reviews 2 (2007).

S. M. Hatfield and M. Sitkovsky, “Oxygenation to Improve Cancer Vaccines, Adoptive Cell Transfer and Blockade of Immunological Negative Regulators,” Oncoimmunology 4, no. 12 (2015): e1052934.

M. L. Margolis et al., “Racial Differences Pertaining to a Belief about Lung Cancer Surgery: Results of a Multicenter Survey,” Annals of Internal Medicine 139, no. 7 (2003): 558–563.

A. James, C. M. Daley, and K. A. Greiner, “‘Cutting’ on Cancer: Attitudes about Cancer Spread and Surgery among Primary Care Patients in the USA,” Social Science and Medicine 73, no. 11 (2011): 1669–1673.

H. V. Ratajczak, R. B. Sothern, and W. J. M. Hrushesky, “Estrous Influence on Surgical Cure of a Mouse Breast Cancer,” Journal of Experimental Medicine 168 (1988): 73–83.

R. A. Badwe et al., “Timing of Surgery During Menstrual Cycle and Survival of Premenopausal Women with Operable Breast Cancer,” The Lancet 337 (1991): 1261–1264; R. Sainsbury et al., “Timing of Surgery for Breast Cancer and Menstrual Cycle,” The Lancet 338 (1991): 391–392.

U. Veronesi et al., “Effect of Menstrual Phase on Surgical Treatment of Breast Cancer,” The Lancet 343 (1994): 1544–1546; R. A. Badwe, I. Mittra, and R. Havaldar, “Timing of Surgery during the Menstrual Cycle and Prognosis of Breast Cancer,” Journal of Biosciences 25, no. 1 (2000): 113–120; I. S. Fentiman, “Timing of Surgery for Breast Cancer,” International Journal of Clinical Practice 56, no. 3 (2002): 188–190; D. Coradini et al., “Fluctuation of Intratumor Biological Variables as a Function of Menstrual Timing of Surgery for Breast Cancer in Premenopausal Patients,” Annals of Oncology 14, no. 6 (2003): 962–964; Z. Saad et al., “Timing of Surgery Influences Survival in Receptor-Negative as Well as Receptor-Positive Breast Cancer,” European Journal of Cancer 30A, no. 9 (1994): 1348–1352; R. T. Senie et al., “Timing of Breast Cancer Excision during the Menstrual Cycle Influences Duration of Disease-Free Survival,” Annals of Internal Medicine 115, no. 5 (1991): 337–342.

A. Goldhirsch et al., “Timing Breast Cancer Surgery,” The Lancet 338 (1991): 691–692; B. Nathan et al., “Timing of Surgery for Breast Cancer in Relation to the Menstrual Cycle and Survival of Premenopausal Women,” British Journal of Surgery 80 (1993): 43; P. Pujol et al., “A Prospective Prognostic Study of the Hormonal Milieu at the Time of Surgery in Premenopausal Breast Carcinoma,” Cancer 91, no. 10 (2001): 1854–1861; Y. Nomura et al., “Lack of Correlation between Timing of Surgery in Relation to the Menstrual Cycle and Prognosis of Premenopausal Patients with Early Breast Cancer,” European Journal of Cancer 35, no. 9 (1999): 1326–1330; Y. Takeda et al., “Does the Timing of Surgery for Breast Cancer in Relation to the Menstrual Cycle or Geomagnetic Activity Affect Prognoses of Premenopausal Patients?” Biomedicine and Pharmacotherapy 57, no. 1 (2003): 96s–103s; A. Mangia et al., “Timing of Breast Cancer Surgery within the Menstrual Cycle: Tumor Proliferative Activity, Receptor Status and Short-Term Clinical Outcome,” Journal of Experimental and Clinical Cancer Research 17, no. 3 (1998): 317–323; G. Mondini et al., “Timing of Surgery Related to Menstrual Cycle and Prognosis of Premenopausal Women with Breast Cancer,” AntiCancer Research 17, no. 1B (1997): 787–790; K. Holli, J. Isola, and M. Hakama, “Prognostic Effect of Timing of Operation in Relation to Menstrual Phase of Breast Cancer Patient – Fact or Fallacy,” British Journal of Cancer 71, no. 1 (1995): 124–127; N. Kroman et al., “Timing of Surgery in Relation to Menstrual Cycle Does Not Predict the Prognosis in Primary Breast Cancer,” European Journal of Surgical Oncology 20, no. 4 (1994): 430–435; M. F. Gnant et al., “Breast Cancer and Timing of Surgery during Menstrual Cycle: a 5-Year Analysis of 385 Premenopausal Women,” International Journal of Cancer 52, no. 4 (1992): 707–712.

W. L. McGuire, “The Optimal Timing of Mastectomy: Low Tide or High Tide,” Annals of Internal Medicine 115 (1991): 401–403.

H. Thorpe et al., “Timing of Breast Cancer Surgery in Relation to Menstrual Cycle Phase: No Effect on 3-Year Prognosis: The ITS Study,” British Journal of Cancer 98, no. 1 (2008): 39–44; C. S. Grant et al., “Menstrual Cycle and Surgical Treatment of Breast Cancer: Findings from the NCCTG N9431 Study,” Journal of Clinical Oncology 27, no. 22 (2009): 3620–3626; P. Pujol et al., “A Prospective Prognostic Study of the Hormonal Milieu at the Time of Surgery in Premenopausal Breast Carcinoma,” Cancer 91 (2001): 1854–1861.

B. Fisher et al., “Reanalysis and Results after 12 Years of Follow-Up in a Randomized Clinical Trial Comparing Total Mastectomy with Lumpectomy with or without Irradiation in the Treatment of Breast Cancer,” New England Journal of Medicine 333 (1995): 1456–1461.

R. Holland et al., “Histologic Multifocality of Tis, T1–2 Breast Carcinomas: Implications for Clinical Trials of Breast-Conserving Surgery,” Cancer 56 (1985): 979–990.

M. Clarke et al., “Effects of Radiotherapy and of Differences in the Extent of Surgery for Early Breast Cancer on Local Recurrence and 15-Year Survival: An Overview of the Randomised Trials,” The Lancet 366 (2005): 2087–2106.

J. Hastings et al., “Risk Factors for Locoregional Recurrence after Mastectomy in Stage T1 N0 Breast Cancer,” American Journal of Clinical Oncology 37, no. 5 (2014): 486–491.

A. McBride et al., “Locoregional Recurrence Risk for Patients with T1, 2 Breast Cancer with 1–3 Positive Lymph Nodes Treated with Mastectomy and Systemic Treatment,” International Journal of Radiation Oncology * Biology * Physics 89, no. 2 (2014): 392–398.

G. Jacobson, et al., “Randomized Trial of Pentoxifylline and Vitamin E vs Standard Follow-Up after Breast Irradiation to Prevent Breast Fibrosis, Evaluated by Tissue Compliance Meter,” International Journal of Radiation Oncology* Biology* Physics 85, no. 3 (2013): 604–608; T. B. Chiao and A. J. Lee, “Role of Pentoxifylline and Vitamin E in Attenuation of Radiation-Induced Fibrosis,” Annals of Pharmacotherapy 39, no. 3 (2005): 516–522.

T. J. Whelan et al., “Long-Term Results of Hypofractionated Radiation Therapy for Breast Cancer,” New England Journal of Medicine 362, no. 6 (2010): 513–520.

T. D. Smile et al., “Accelerated Partial-Breast Irradiation: An Emerging Standard of Care,” Applied Radiation Oncology , http://appliedradiationoncology.com/articles/accelerated-partial-breast-irradiation-an-emerging-standard-of-care.